The FDA assigned an April 9, 2027, PDUFA date to rivoceranib plus camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
|Videos|November 5, 2020
Evolving Approaches for HCC in the Molecular Medicine Era
Author(s)Targeted Oncology
An in-depth discussion on the targeting of specific molecular pathways with newer, novel therapies to better manage patients with liver cancer.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Onc
1
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
2
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
3
Obrixtamig Shows Activity in First-Line epNEC, Regardless of DLL3 Expression Level
4
Radioligand Therapy Trials Begin Reshaping Neuroendocrine Tumor Care
5